Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Addison’s Disease Market Size Changed, over the years?
In recent times, the market size of Addison’s disease has expanded swiftly. The anticipated growth is from $2.05 billion in 2024 to around $2.25 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%. Factors leading to this growth during the historic period include the global upsurge in Addison’s disease cases, enhanced awareness about adrenal insufficiency, an increase in healthcare spending, a surge in autoimmune diseases, and the expanding elderly population.
How Much Will the Addison’s Disease Market Be Worth in 2029?
Expectations are high for significant expansion in the Addison’s disease market in the coming years, with projections putting it at $3.26 billion by 2029, progressing at a compound annual growth rate (CAGR) of 9.7%. This projected growth during the forecast period is linked with the heightened demand for superior therapeutic options, an increased emphasis on early detection, a surge in cases of congenital adrenal hyperplasia, expansion of telemedicine services, and an increasing number of adrenal tuberculosis instances. Key trends for the forecast period include enhancements in laboratory testing techniques, progress in hormone replacement therapies, improvements in imaging technologies, the creation of long-term injectable formulations, and the incorporation of artificial intelligence into diagnostic tools.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21084&type=smp
Which is the Largest Company in the Addison’s Disease Market?
Major companies operating in the addison’s disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, Roxane Laboratories Inc.
What Are the Main Market Drivers in the Addison’s Disease Industry?
The increasing occurrence of autoimmune diseases is projected to fuel the expansion of the Addison’s disease market in the future. Autoimmune diseases happen when the immune system accidentally attacks the body’s own healthy tissues, leading to inflammation and damage. Hereditary tendencies, environmental influencers like pollutants and shifts in diet, and lifestyle factors such as stress and physical inactivity all play roles in the upswing of autoimmune diseases. The rising frequency of these diseases is boosting the potential of simultaneous occurrence with Addison’s disease, given that many patients develop further autoimmune conditions. For example, Versorgungsatlas.de, a German-based organization, reported in November 2024 that 6,304,340 out of 73,241,305 insured individuals were diagnosed with an autoimmune disease in 2022, taking the gross prevalence rate to 8.61%. This surpasses previous estimates of between 3% and 9%. Consequently, this escalating occurrence of autoimmune diseases is propelling the growth of the Addison’s disease market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21084&type=smp
How Is the Addison’s Disease Market Segments Structured?
The addison’s disease market covered in this report is segmented –
1) By Type: Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency
2) By Drug Class: Oral Corticosteroid, Hydrocortisone, Fludrocortisone, Corticosteroid Injections
3) By Diagnosis: Laboratory Testing, Imaging Testing
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Primary Adrenal Insufficiency: Autoimmune Addison’s Disease, Infectious Addison’s Disease, Other causes of primary adrenal insufficiency
2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction, Hypothalamic dysfunction
3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use, Other causes of tertiary adrenal insufficiency
What Strategic Trends Are Transforming the Addison’s Disease Market?
Leading businesses in the Addison’s disease market are concentrating their efforts on innovative solutions, including regenerative therapies. The aim is to improve treatment alternatives, enhance patient outcomes, and potentially reduce life-long reliance on hormone replacement therapies by stimulating the body’s natural adrenal function. In the medical field, regenerative therapies are focused on restoring or regenerating human cells, tissues, or organs, which is very helpful in case of injury, disease, or degeneration. In an example from July 2024, Eton Pharmaceuticals, Inc., a U.S. public pharmaceutical company that specializes in developing and marketing unique treatments for uncommon diseases, announced that the FDA approved their New Drug Application (NDA) for ET-400, a unique formulation of hydrocortisone oral solution. Compared to other formulations that may require refrigeration, ET-400 is easier to store and transport. The liquid format is particularly beneficial for younger patients who may struggle with swallowing traditional pills, and it allows for precise dosing.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/addisons-disease-global-market-report
Which Global Regions Offer the Highest Growth in the Addison’s Disease Market?
North America was the largest region in the addison’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21084
This Report Delivers Insight On:
1. How big is the addison’s disease market, and how is it changing globally?
2. Who are the major companies in the addison’s disease market, and how are they performing?
3. What are the key opportunities and risks in the addison’s disease market right now?
4. Which products or customer segments are growing the most in the addison’s disease market?
5. What factors are helping or slowing down the growth of the addison’s disease market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model